Novo Nordisk gatecrashes Pfizer deal with $9bn bid for Metsera

Mark Kelly, chief executive of advisory firm MKI Global Partners, said the deal had become “very political” and the structure was a sign that Novo had “no confidence itself in getting antitrust approvals done anywhere near as smoothly as Pfizer would”

Published by and image courtesy of Financial Times